Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16611 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Xing Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, China. Hauptthemen laut MEDLINE: Coumaric Acids, Dermatologic Agents, Rosacea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Doctoral Startup Fund of Affiliated Hospital of Shandong Second Medical University.
Abstract (Originalsprache)
Background
Rosacea is a chronic inflammatory skin disease characterized by flushing, erythema, papules, and pustules on the central face. It affects patient appearance and is noted for its chronicity, recurrence, and resistance to treatment. Effective rosacea treatment requires repairing the skin barrier, reducing inflammation, and promoting vasoconstriction.
Aims
This study aims to evaluate the efficacy of topical ferulic acid in treating papulopustular rosacea and its impact on skin barrier function.
Methods
Sixty patients with mild to moderate papulopustular rosacea were selected from the Department of Dermatology at the Affiliated Hospital of Shandong Second Medical University between January 2023 and December 2023. Patients were randomly assigned to either a control group or an observation group, with 30 patients in each group. The observation group applied ferulic acid solution to the affected areas, while the control group used normal saline, both twice daily for 6 weeks. Both groups also received 0.1 g doxycycline hydrochloride tablets orally once daily. Skin lesions and skin barrier function were assessed using VISIA imaging and self‐rating scales before and during treatment, and adverse reactions were recorded.
Results
After 6 weeks, both skin lesion assessments and self‐assessment scores improved significantly from baseline, with greater improvement in the observation group compared to the control group ( p < 0.05). Indicators of skin barrier function and VISIA imaging results demonstrated the efficacy of ferulic acid in treating rosacea. The total effective rate was significantly higher in the observation group (80.00%) compared to the control group (63.33%) ( p < 0.05). In the observation group, nine patients (30.00%) experienced a greasy sensation initially, one patient (3.33%) reported tingling and itching, and no serious adverse reactions were observed.
Conclusions
Ferulic acid is effective as an adjuvant treatment for papulopustular rosacea, significantly improving skin lesions and repairing skin barrier function with minimal adverse reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, China.
- Yantai Xianse Trading Co., Ltd., Yantai, Shandong, China.
Förderung
- Doctoral Startup Fund of Affiliated Hospital of Shandong Second Medical University
Zitieren
APA
Wang, X., Xue, Y., Zhu, H., Zhang, J., Li, M., Ge, W., Luo, Z., Yuan, X., Zhang, D., & Ma, W. (2025). Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16611
Vancouver
Wang X, Xue Y, Zhu H, Zhang J, Li M, Ge W, et al. Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16611
BibTeX
@article{Wang2025,
author = {Wang, Xing and Xue, Yonghong and Zhu, Hongzi and Zhang, Jingjie and Li, Meiling and Ge, Wenxiu and Luo, Zengxiang and Yuan, Xiangfeng and Zhang, Dong and Ma, Weiyuan},
title = {Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16611}
}
EUVIMED